LivingGLP1
Study S000734

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects

Registration

Registration
NCT06054698
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
TRIPLE
Status
COMPLETED
Enrollment
61
Start
2023-10-16
Primary completion
2024-09-09
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions
Overweight or Obesity
Interventions
DRUG:HRS9531 injection; DRUG:HRS9531 injection Placebo
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Percentage change in body weight [Week 0, Week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.